alpha-Mannosidosis: Clinical Trials

8 trials for alpha-Mannosidosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 2 terminated, 1 active not recruiting, 1 recruiting. 8 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 28Completed 3, Terminated 2, Active not recruiting 1, Recruiting 1, Unknown 1
Phase 11Terminated 1

Follow alpha-Mannosidosis: new trials by email Literature Review of alpha-Mannosidosis trials Research Report on alpha-Mannosidosis

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Trial on Safety and Efficacy of Velmanase Alfa Treatment in Pediatric Patients With Alpha-Mannosidosis
Velmanase Alfa (e.g. Lamazym) - Alpha-Mannosidosis
Phase 2CompletedChiesi Farmaceutici S.p.A.52016-12-012021-10-26
MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis
Stem Cell Transplantation, IMD Preparative Regimen, Osteopetrosis Only Preparative Regimen - Mucopolysaccharidosis Disorders, Hurler Syndrome
Phase 2Active not recruitingMasonic Cancer Center, University of Minnesota1492014-07-102026-01-07
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
Hydroxyurea, Alemtuzumab, Fludarabine - Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes
Phase 2RecruitingPaul Szabolcs1002014-02-042025-12-15
Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-Mannosidosis
Lamazym - Alpha-Mannosidosis
Phase 2CompletedZymenex A/S102012-01-012017-03-29
Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders
hematopoietic stem cell infusion - Hurler Syndrome (MPS I), Hurler-Scheie Syndrome
Phase 1 / Phase 2TerminatedTalaris Therapeutics Inc.32011-04-012023-04-12
Dose Finding Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis
Lamazym - Alpha Mannosidosis
Phase 2UnknownZymenex A/S102011-01-012012-09-26
Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders
Campath-1H, Cyclophosphamide, Busulfan - Mucopolysaccharidosis, Hurler Syndrome
Phase 2CompletedMasonic Cancer Center, University of Minnesota462009-12-012018-02-05
Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism
Stem Cell Transplantation, Cyclophosphamide, Campath-1H - Hurler's Syndrome, Maroteaux-Lamy Syndrome
Phase 2TerminatedMasonic Cancer Center, University of Minnesota182008-03-012017-12-28

Narrower conditions

Leukodystrophy, Globoid Cell (5)  ·  Leukodystrophy, Metachromatic (5)  ·  Mucopolysaccharidosis I (5)  ·  Mucopolysaccharidosis II (4)  ·  Adrenoleukodystrophy (3)  ·  Aspartylglucosaminuria (3)  ·  Fucosidosis (3)  ·  Mucopolysaccharidosis VI (3)  ·  Mucopolysaccharidosis VII (3)  ·  Peroxisomal Disorders (3)  ·  Sphingolipidoses (3)  ·  Hereditary Diffuse Leukoencephalopathy with Spheroids (2)  ·  Mucopolysaccharidoses (2)  ·  Osteopetrosis (2)

Broader conditions

Carbohydrate Metabolism, Inborn Errors (8)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8)  ·  Genetic Diseases, Inborn (8)  ·  Lysosomal Storage Diseases (8)  ·  Mannosidase Deficiency Diseases (8)  ·  Metabolic Diseases (8)  ·  Nutritional and Metabolic Diseases (8)  ·  Metabolism, Inborn Errors (7)  ·  Brain Diseases (5)  ·  Brain Diseases, Metabolic (5)  ·  Brain Diseases, Metabolic, Inborn (5)  ·  Central Nervous System Diseases (5)  ·  Connective Tissue Diseases (5)  ·  Demyelinating Diseases (5)  ·  Hereditary Central Nervous System Demyelinating Diseases (5)

Interventions

Stem Cell Transplantation (4)  ·  Alemtuzumab (3)  ·  Busulfan (2)  ·  Cyclophosphamide (2)  ·  Bone Marrow Transplantation (1)  ·  Cyclosporine (1)  ·  Hydroxyurea (1)  ·  Melphalan (1)  ·  Mycophenolic Acid (1)  ·  Regimen B (1)  ·  Thiotepa (1)  ·  fludarabine (1)  ·  fludarabine phosphate (1)

Sponsors

Masonic Cancer Center, University of Minnesota (3)  ·  Zymenex A/S (2)  ·  Chiesi Farmaceutici S.p.A. (1)  ·  Paul Szabolcs (1)  ·  Talaris Therapeutics Inc. (1)

Countries

United States (5)  ·  Denmark (3)  ·  Austria (1)  ·  Belgium (1)  ·  France (1)  ·  Germany (1)  ·  Italy (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Jens Fogh (2)  ·  Paul Orchard, MD (2)  ·  Allan M Lund, MD (1)  ·  Allan M. Lund, MD (1)  ·  Paul Orchard, M.D. (1)  ·  Paul Szabolcs, MD (1)  ·  Suzanne T Ildstad, MD (1)

Results publications

PMID 21586746, PMID 32634238, PMID 32750127

NIH funding

2016 (1)